Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Increased to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Day One Biopharmaceuticals to a "Hold"; the stock has a consensus Hold rating with an average price target of $23.29 and an analyst split of 1 Buy, 8 Hold, 1 Sell.
• DAWN opened at $21.53 (its 12‑month high) with a market cap of $2.22 billion, but reported a quarterly EPS of ($0.21) versus ($0.17) expected (revenue beat), and shows a negative net margin (67.85%) and negative ROE; analysts forecast -0.86 EPS for the year.
• Insiders sold 36,461 shares (~$422,948) in the last quarter and now own 6.20% of the company, while institutional investors and hedge funds hold about 87.95% of the stock.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) was upgraded by stock analysts at Wall Street Zen to a "hold" rating in a research note issued to investors on Saturday.

Other equities analysts have also issued reports about the stock. Wedbush reissued a "neutral" rating and issued a $21.50 target price (down from $30.00) on shares of Day One Biopharmaceuticals in a report on Monday, March 9th. TD Cowen lowered shares of Day One Biopharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, March 6th. Oppenheimer reissued a "market perform" rating on shares of Day One Biopharmaceuticals in a report on Friday, March 6th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $21.50 target price (down from $27.00) on shares of Day One Biopharmaceuticals in a report on Wednesday, March 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of "Hold" and an average price target of $23.29.

Day One Biopharmaceuticals Price Performance

DAWN stock opened at $21.53 on Friday. Day One Biopharmaceuticals has a 12 month low of $5.64 and a 12 month high of $21.53. The firm has a market cap of $2.22 billion, a P/E ratio of -20.90 and a beta of -1.74. The company's 50-day moving average price is $18.63 and its two-hundred day moving average price is $12.50.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Equities analysts predict that Day One Biopharmaceuticals will post -0.86 EPS for the current year.

Insider Buying and Selling

In other news, CFO Charles N. York II sold 6,065 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $70,354.00. Following the sale, the chief financial officer directly owned 312,025 shares in the company, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Vasconcelles sold 2,728 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares in the company, valued at approximately $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,461 shares of company stock worth $422,948 in the last quarter. Corporate insiders own 6.20% of the company's stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the stock. AIGH Capital Management LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at approximately $10,719,000. AlphaQuest LLC boosted its position in Day One Biopharmaceuticals by 1,065.6% during the 3rd quarter. AlphaQuest LLC now owns 185,006 shares of the company's stock worth $1,304,000 after buying an additional 169,134 shares during the period. Mak Capital One LLC acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $10,212,000. Hennion & Walsh Asset Management Inc. boosted its position in Day One Biopharmaceuticals by 229.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 313,455 shares of the company's stock worth $2,921,000 after buying an additional 218,383 shares during the period. Finally, Algert Global LLC boosted its position in Day One Biopharmaceuticals by 45.4% during the 3rd quarter. Algert Global LLC now owns 1,317,042 shares of the company's stock worth $9,285,000 after buying an additional 411,000 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company's pipeline includes several small-molecule candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.